Myriad Genetics, Inc. · NASDAQ:MYGN
Myriad Genetics — Merger or Acquisition (May 2016)
21 slides from Myriad Genetics's merger presentation, May 31, 2016
Slide 1: Myriad Genetics Acquisition of Sividon Diagnostics
Myriad Genetics Acquisition of Sividon Diagnostics 05/31/2016 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or res
Slide 3: Acquisition of Sividon Diagnostics: Consideration and Rationale
Myriad Genetics Acquisition of Sividon Diagnostics Consideration For Sividon Shareholders Acquired Sividon for €35M upfront and €15M in performance based milestones FY17 EndoPredict revenues estimated to be $8M (not including U.S. revenue) Funding deal using cash on hand Closed May 31, 2016 Myriad F
Slide 4: Strategic Rationale: Substantial Market Opportunity
Strategic Rationale Substantial market opportunity Broadens comprehensive product offering in oncology Best in class product Synergistic product within strategy
Slide 5: Synergistic Product Within 4in6 Strategy
Synergistic Product Within Strategy Currently Marketed Under Development Risk? Diagnosis? Prognosis? Therapy? Oncology Preventive Care Urology Dermatology Neuroscience Autoimmune
Slide 6: Significant Ability to Leverage Myriad's Existing Sales Infrastructure
Significant Ability to Leverage Myriad’s Existing Sales Infrastructure Sold through Myriad’s 150 person oncology sales team Sold through Myriad’s international sales force and distributor network
Slide 7: Strategic Rationale: Substantial Market Opportunity
Strategic Rationale Substantial market opportunity Broadens comprehensive product offering in oncology Best in class product Synergistic product within strategy
Slide 8: Expanding Reimbursement Profile
Expanding Reimbursement Profile COUNTRY REIMBURSEMENT STATUS U.S. Aetna announced positive coverage decision in May 2016; Noridian/MolDx proposed coverage based on ASCO guidelines Germany Expected in CY16 France Provisional funding approved April 2016 UK Submission to NICE in CY16 Italy Tender based
Slide 9: Building Towards >$600M Global Market
Building Towards >$600M Global Market $31M $9M $52M $54M $50M $66M $305M FY20 Market Penetration Revenue 5% $33M 10% $66M 25% $165M Currently at about 10% market penetration in Germany and Switzerland $100M
Slide 10: Myriad Uniquely Positioned to Capture Market Share
Myriad Uniquely Positioned to Capture Market Share Pathology/Oncology Customer One Source for Cancer Patients Kit Based with Shared Economics and local testing Superior Clinical Performance of EndoPredict Strength of Myriad Sales and Marketing
Slide 11: Strategic Rationale: Best in Class Product
Strategic Rationale Substantial market opportunity Broadens comprehensive product offering in oncology Best in class product Synergistic product within strategy
Slide 12: Best in Class Product: Competitive Differentiators
Best in Class Product Competitive Differentiators Data Outperforms first generation breast prognostic in head to head study No Intermediate Risk Group Does not provide ambiguous intermediate risk classification Kit Based Format Ability to be performed by local laboratory with shared economics 1 2 3
Slide 13: Best in Class Product Supported by Strong Data
Best in Class Product Supported by Strong Data Name of Trial # of Patients Nodal Status Distant Metastases Rate in Low Risk Group P value Multicenter training set 964 N0, N+ 7% P < 0.001 ABCSG-6 378 N0, N+ 4% P < 0.001 ABCSG-8 1,324 N0, N+ 4% P < 0.001 GEICAM/9906 555 N+ 0% P < 0.001 TransATAC Submi
Slide 14: EndoPredict Outperformed Market Leading Test in Head to Head Study
EndoPredict Outperformed Market Leading Test in Head to Head Study Study EndoPredict (clin) 1st Generation Test Node Negative Low Risk 10-year Mets 5.9% 5.3% Hazard ratio 3.92 3.72 Node Positive Low Risk 10-year Mets 5.0% 25.1% Hazard ratio 9.49 1.88 % Intermediate 0% ≈22% TransATAC Study: 928 Patie
Slide 15: Guidelines Support EndoPredict
Guidelines Support EndoPredict Guideline Recommendation “If a patient has ER/PgR-positive, HER2-negative (node-negative) breast cancer, the clinician may use the 12-gene risk score (EndoPredict; Sividon Diagnostics, Koln, Germany) to guide decisions on adjuvant systemic chemotherapy.” St.Gallen Inte
Slide 16: EndoPredict Has No Intermediate Classification
EndoPredict Has No Intermediate Classification *Paik et al. NEJM 2004 1st Generation Test*
Slide 17: Foundational Product for Global Kit Strategy
Foundational Product for Global Kit Strategy RNA Expression Protein In discussions with potential partners
Slide 18: Kit Model Presents Viable Solution
Kit Model Presents Viable Solution HOSPITAL LABORATORY Outside the United States there is a strong desire for in- country testing and select markets require in-country testing Sells Kit Lab runs test on site 3 Interprets data with proprietary cloud-based algorithms 1 2 4 Lab bills and obtains reimbu
Slide 19: Strategic Rationale: Broadens Product Offering in Oncology
Strategic Rationale Substantial market opportunity Broadens comprehensive product offering in oncology Best in class product Synergistic product within strategy
Slide 20: Broadens Comprehensive Product Offering in Oncology
RISK ASSESSMENT Broadens Comprehensive Product Offering in Oncology PROGNOSIS THERAPY SELECTION Breast Cancer Patient
Slide 21: Acquisition of Sividon Diagnostics: Consideration and Rationale
Myriad Genetics Acquisition of Sividon Diagnostics Consideration For Sividon Shareholders Acquired Sividon for €35M upfront and €15M in performance based milestones FY17 EndoPredict revenues estimated to be $8M (not including U.S. revenue) Funding deal using cash on hand Closed May 31, 2016 Myriad F